Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the initial and rate-limiting step of the catabolic pathway of toxic metabolites of 5-fluorouracil (5-FU). Several studies have reported that deficiency of DPD and polymorphisms of its gene are related to...
Saved in:
Main Authors: | Teh, Lay Kek, Hamzah, Sharina, Hashim, Hazwanie, Bannur, Zakaria, Zakaria, Zainul Amiruddin, Hasbullani, Zakaria, Kwong, John Siew Shia, Fijeraid, Henry, Md Nor, Azmid, Mohd Zailani,, Ramasamy, Prabu, Ngow, Harris, Sood, Suneet, Salleh, Mohd Zaki |
---|---|
Format: | Article |
Language: | English |
Published: |
Lippincott Williams & Wilkins
2013
|
Online Access: | http://psasir.upm.edu.my/id/eprint/29679/1/Potential%20of%20dihydropyrimidine%20dehydrogenase%20genotypes%20in%20personalizing%205.pdf http://psasir.upm.edu.my/id/eprint/29679/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential of dihydropyrimidine dehydrogenase genotypes in personalising 5-fluorouracil therapy among colorectal cancer patients
by: Ngow, Harris Abdullah, et al.
Published: (2011) -
Metabolomics and pharmacogenetics based 5-fluorouracil monitoring in colorectal cancer patients
by: Zakaria, Bannur, et al.
Published: (2014) -
Metabolomics and pharmacogenetics based 5-fluorouracil monitoring in colorectal cancer patients
by: Bannur, Zakaria, et al.
Published: (2014) -
Integrating pharmacogenomics- metabolomics towards realising personalised medicine for colorectal cancer patients treated with 5-fluorouracil / Hazwanie Hashim
by: Hashim, Hazwanie
Published: (2012) -
Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells
by: Lau, Meng Fei, et al.
Published: (2018)